Trial Profile

AFIRE Study: Atrial Fibrillation and Ischemic events with Rivaroxaban in patiEnts with stable coronary artery disease Study

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Aug 2022 Results of post-hoc analysis assessing outcomes of rivaroxaban monotherapy (vs. combination therapy) in patients with atrial fibrillation and stable coronary artery disease across body mass index categories, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
13 Jun 2022 Results published in the Thrombosis and Haemostasis
14 Jul 2021 Results (n= 1075) of pre-specified sub-analysis assessing efficacy and safety of P2Y12 inhibitors and aspirin in patients with stable CAD and AF, published in the Heart.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com